{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Solid+Malignancy&page=34", "query": { "condition": "Solid Malignancy", "page": 34 }, "page_size": 10 }, "pagination": { "page": 34, "page_size": 10, "total_count": 5456, "total_pages": 546, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Solid+Malignancy&page=35&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Solid+Malignancy&page=33&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-26T12:21:56.631Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07612488", "title": "A Study of CS231295 in Patients With Advanced Solid Tumors", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advance Solid Tumors", "Advanced Malignant Solid Tumors" ], "interventions": [ { "name": "a small molecular multi-target kinase inhibitor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ThalassaX Therapeutics United States Ltd", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2026-06", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2026-05-28", "last_synced_at": "2026-10-26T12:21:56.631Z", "location_count": 4, "location_summary": "Denver, Colorado • Sarasota, Florida • Boston, Massachusetts + 1 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT07612488" }, { "nct_id": "NCT00067288", "title": "Meaning-Centered Psychotherapy in Advanced Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma, Non-Hodgkin", "Neoplasms" ], "interventions": [ { "name": "Meaning-Centered Group Psychotherapy", "type": "BEHAVIORAL" }, { "name": "Standard Supportive Group Psychotherapy", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "National Center for Complementary and Integrative Health (NCCIH)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 118, "start_date": "2002-05", "completion_date": "2006-03", "has_results": false, "last_update_posted_date": "2006-08-18", "last_synced_at": "2026-10-26T12:21:56.631Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00067288" }, { "nct_id": "NCT07123103", "title": "A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "XB371", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Exelixis", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 150, "start_date": "2025-08-18", "completion_date": "2028-02", "has_results": false, "last_update_posted_date": "2026-02-17", "last_synced_at": "2026-10-26T12:21:56.631Z", "location_count": 9, "location_summary": "Rogers, Arkansas • Los Angeles, California • Washington D.C., District of Columbia + 6 more", "locations": [ { "city": "Rogers", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Orlando", "state": "Florida" }, { "city": "Grand Rapids", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT07123103" }, { "nct_id": "NCT02161770", "title": "Study to Assess the Blood Levels and Safety of AZD9291 in Patients With Advanced Solid Tumours and Normal Liver Function or Mild or Moderate Liver Impairment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumours" ], "interventions": [ { "name": "AZD9291 tablet dosing", "type": "DRUG" }, { "name": "Pharmacokinetic sampling - AZD9291", "type": "PROCEDURE" }, { "name": "Pharmacokinetic sampling - AZ5140 and AZ7550", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 30, "start_date": "2014-12-22", "completion_date": "2017-08-22", "has_results": false, "last_update_posted_date": "2019-03-08", "last_synced_at": "2026-10-26T12:21:56.631Z", "location_count": 5, "location_summary": "San Diego, California • Atlanta, Georgia • Detroit, Michigan + 2 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02161770" }, { "nct_id": "NCT01836705", "title": "Effect of SAR302503 on ECG Activity in Patients With Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasm Malignant" ], "interventions": [ { "name": "SAR302503 (TG101348)", "type": "DRUG" }, { "name": "Placebo SAR302503", "type": "DRUG" }, { "name": "Panolosetron", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2013-05", "completion_date": "2014-05", "has_results": false, "last_update_posted_date": "2025-03-05", "last_synced_at": "2026-10-26T12:21:56.631Z", "location_count": 8, "location_summary": "Los Angeles, California • Augusta, Georgia • Detroit, Michigan + 4 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Detroit", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01836705" }, { "nct_id": "NCT00687505", "title": "Safety Study of FP-1039 To Treat Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Cancer" ], "interventions": [ { "name": "FP-1039", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Five Prime Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 39, "start_date": "2008-07", "completion_date": "2011-06", "has_results": false, "last_update_posted_date": "2021-12-13", "last_synced_at": "2026-10-26T12:21:56.631Z", "location_count": 2, "location_summary": "Detroit, Michigan • San Antonio, Texas", "locations": [ { "city": "Detroit", "state": "Michigan" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00687505" }, { "nct_id": "NCT07492680", "title": "A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "BMS-986504", "type": "DRUG" }, { "name": "Daraxonrasib", "type": "DRUG" }, { "name": "Nivolumab + Relatlimab FDC", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Pumitamig", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 260, "start_date": "2026-07-27", "completion_date": "2032-05-20", "has_results": false, "last_update_posted_date": "2026-10-06", "last_synced_at": "2026-10-26T12:21:56.631Z", "location_count": 16, "location_summary": "San Francisco, California • Aurora, Colorado • Atlanta, Georgia + 10 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07492680" }, { "nct_id": "NCT00635284", "title": "ABI-009 Trial in Patients With Advanced Non-hematologic Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "ABI-009", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2007-12-01", "completion_date": "2011-06-01", "has_results": false, "last_update_posted_date": "2019-10-18", "last_synced_at": "2026-10-26T12:21:56.631Z", "location_count": 2, "location_summary": "Santa Monica, California • Houston, Texas", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00635284" }, { "nct_id": "NCT00005078", "title": "Tirapazamine, Carboplatin, and Paclitaxel in Treating Patients With Advanced Malignant Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "carboplatin", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "tirapazamine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 44, "start_date": "2000-03", "completion_date": "2012-07", "has_results": false, "last_update_posted_date": "2015-06-08", "last_synced_at": "2026-10-26T12:21:56.631Z", "location_count": 4, "location_summary": "Duarte, California • Los Angeles, California • Pasadena, California + 1 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Pasadena", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00005078" }, { "nct_id": "NCT00475917", "title": "A Study of XL844 Administered as a Single Agent and in Combination With Gemcitabine in Adults With Advanced Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer", "Lymphoma" ], "interventions": [ { "name": "XL844", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Exelixis", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2007-05", "completion_date": "2008-12", "has_results": false, "last_update_posted_date": "2015-08-21", "last_synced_at": "2026-10-26T12:21:56.631Z", "location_count": 2, "location_summary": "New York, New York • Houston, Texas", "locations": [ { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00475917" } ] }